In the US, Bosulif (bosutinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Chronic Myelogenous Leukemia.
Ingredient matches for Bosulif
Bosutinib is reported as an ingredient of Bosulif in the following countries:
- Croatia (Hrvatska)
- United States
Bosutinib hydrate (a derivative of Bosutinib) is reported as an ingredient of Bosulif in the following countries:
- United Kingdom
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.